Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects

被引:42
作者
Anderson, Lindsey J. [1 ]
Tamayose, Jamie M. [1 ]
Garcia, Jose M. [1 ,2 ]
机构
[1] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA
[2] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA
关键词
Drug abuse; Performance enhancing drugs; Muscle; Side effects; Doping; Sports; RECOMBINANT HUMAN GH; PERFORMANCE-ENHANCING DRUGS; SKELETAL-MUSCLE HYPERTROPHY; FOXO TRANSCRIPTION FACTORS; QUALITY-OF-LIFE; BODY-COMPOSITION; DEFICIENT ADULTS; LONG-TERM; ANDROGENIC STEROIDS; RESISTANCE EXERCISE;
D O I
10.1016/j.mce.2017.06.010
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Hormones with anabolic properties such as growth hormone (GH), insulin-like growth factor-1 (IGF-I), and insulin are commonly abused among professional and recreational athletes to enhance physical ability. Performance enhancing drugs (PEDs) such as these are also commonly used by recreational athletes to improve body aesthetics. The perception of increased muscle mass due to supraphysiologic hormone supplementation, or doping, is widespread among PED users despite a paucity of evidence based data in humans. Even still, athletes will continue to abuse PEDs in hopes of replicating anecdotal results. It is important to educate the general public and potential treating physicians of the risks of PED use, including the dangers of polypharmacy and substance dependence. It will also be important for the research community to address the common challenges associated with studying PED use such as the ethical considerations of PED administration, the general reticence of the PED-using community to volunteer information, and the constant need to improve or create new detection methods as athletes continually attempt to circumvent current methods. This review highlights the anabolic mechanisms and suggestive data implicating GH, IGF-I, and insulin for use as PEDs, the specific detection methods with cutoff ranges that may be utilized to diagnose abuse of each substance, and their respective side effects. Published by Elsevier Ireland Ltd.
引用
收藏
页码:65 / 74
页数:10
相关论文
共 133 条
[1]  
2010 World Anti-Doping Agency Guidelines, 2010, 2010 WORLD ANTI DOPI
[2]   Differential effects of insulin-like growth factor-I on matrix and DNA synthesis in various regions and types of rabbit tendons [J].
Abrahamsson, SO ;
Lohmander, S .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1996, 14 (03) :370-376
[3]   GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults [J].
Allen, D. B. ;
Backeljauw, P. ;
Bidlingmaier, M. ;
Biller, B. M. K. ;
Boguszewski, M. ;
Burman, P. ;
Butler, G. ;
Chihara, K. ;
Christiansen, J. ;
Cianfarani, S. ;
Clayton, P. ;
Clemmons, D. ;
Cohen, P. ;
Darendeliler, F. ;
Deal, C. ;
Dunger, D. ;
Erfurth, E. M. ;
Fuqua, J. S. ;
Grimberg, A. ;
Haymond, M. ;
Higham, C. ;
Ho, K. ;
Hoffman, A. R. ;
Hokken-Koelega, A. ;
Johannsson, G. ;
Juul, A. ;
Kopchick, J. ;
Lee, P. ;
Pollak, M. ;
Radovick, S. ;
Robison, L. ;
Rosenfeld, R. ;
Ross, R. J. ;
Savendahl, L. ;
Saenger, P. ;
Sorensen, H. Toft ;
Stochholm, K. ;
Strasburger, C. ;
Swerdlow, A. ;
Thorner, M. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2016, 174 (02) :P1-P9
[4]   A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies [J].
Andersen, L ;
Jorgensen, PN ;
Jensen, LB ;
Walsh, D .
CLINICAL BIOCHEMISTRY, 2000, 33 (08) :627-633
[5]  
[Anonymous], 2016, BUSHEHR ASIAN J SPOR, DOI DOI 10.5812/ASJSM.35018
[6]  
[Anonymous], OXFORD TXB ENDOCRINO
[7]   Hormone abuse, in sports: the antidoping perspective [J].
Barroso, Osquel ;
Mazzoni, Irene ;
Rabin, Olivier .
ASIAN JOURNAL OF ANDROLOGY, 2008, 10 (03) :391-402
[8]   Growth Hormone Doping in Sports: A Critical Review of Use and Detection Strategies [J].
Baumann, Gerhard P. .
ENDOCRINE REVIEWS, 2012, 33 (02) :155-186
[9]  
BENGTSSON BA, 1988, ACTA MED SCAND, V223, P327
[10]   TREATMENT OF ADULTS WITH GROWTH-HORMONE (GH) DEFICIENCY WITH RECOMBINANT HUMAN GH [J].
BENGTSSON, BA ;
EDEN, S ;
LONN, L ;
KVIST, H ;
STOKLAND, A ;
LINDSTEDT, G ;
BOSAEUS, I ;
TOLLI, J ;
SJOSTROM, L ;
ISAKSSON, OGP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 76 (02) :309-317